ErbB2 antibody | 4D5-8

100% Secure


Human anti ErbB2 (Trastuzumab Biosimilar)

Anti-ErbB2 Antibody is a non-therapeutic biosimilar of the monoclonal antibody drug trastuzumab (Herceptin) for research use. It can be used in bioanalytical PK and ADA assays and for studying biological pathways affected by the drug.

Product Type
Monoclonal Antibody
Clone
4D5-8
Isotype
IgG1
Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
MCA6092 E 0.2 mg
Human Anti-ErbB2 antibody, clone 4D5-8 is a research grade biosimilar of the monoclonal antibody drug trastuzumab. It is a recombinant human IgG1 kappa antibody with variable regions from the therapeutic trastuzumab antibody clone 4D5-8.

Human Anti-ErbB2 antibody, clone 4D5-8 is for research use only. It is suitable as a reference standard in a pharmacokinetic (PK) bridging ELISA with anti-trastuzumab antibodies, for example HCA168 and HCA167. It can also be used as capture and detection reagent in an anti-drug antibody (ADA) bridging ELISA, with an anti-trastuzumab antibody in IgG1 format as a reference standard, for example HCA176 or HCA177.

Trastuzumab, also known as Herceptin, is a drug used in the treatment of HER2 positive breast cancer and other HER2 over-expressing cancers including HER2-positive metastatic cancers of the gastrointestinal tract. Trastuzumab binds to the HER2 (or c-erbB2) proto-oncogene, an EGF receptor-like protein found on 20-30% of breast cancer cells. The binding leads to antibody mediated (complement mediated) killing of the HER2 positive cells.

This product is NOT FOR THERAPEUTIC USE.

View a summary of supporting anti-trastuzumab antibody products.

Product Details

Target Species
Human
Product Form
Human IgG1 (kappa) antibody - liquid
Preparation
Purified IgG prepared by affinity chromatography on Protein A
Buffer Solution
Phosphate buffered saline
Preservative Stabilisers
0.02% Proclin 300
Immunogen
A431 cells (human epidermoid carcinoma) (over)expressing EGFR
Purity
>98% by SDS PAGE
Approx. Protein Concentrations
IgG concentration 1.0 mg/ml

Storage Information

Storage
Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Shelf Life
12 months from date of despatch

More Information

Licensed Use
For in vitro research purposes only. Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Regulatory
For research purposes only

Applications of ErbB2 antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
ELISA
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Useful Reagents Available

Description Product Code Pack Size Applications List Price Quantity
Hispec Assay Diluent BUF049A 50 ml E IY
Human anti Trastuzumab HCA166 0.1 mg E
Human anti Trastuzumab HCA167 0.1 mg E
Human anti Trastuzumab HCA168 0.1 mg E
Human anti Trastuzumab HCA169 0.1 mg E
Human anti Trastuzumab HCA176 0.1 mg E
Human anti Trastuzumab:HRP HCA176P 0.1 mg E
Human anti Trastuzumab HCA177 0.1 mg E
Human anti Trastuzumab:HRP HCA177P 0.1 mg E
Human anti Trastuzumab (Drug/Target Complex) HCA263 0.1 mg E
Human anti Trastuzumab HCA270 0.1 mg E
LYNX Rapid HRP Antibody Conjugation Kit LNK001P 1 Conjugation For 400µg Antibody CJ

Product Specific References

Further Reading

  1. Pivot, X. et al. (2015) Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations.
    Anticancer Drugs. 26 (10): 1009-16.